Author, Subjects, Keywords

Cited Author

 
 
   » By Author or Editor
 » Browse Author by Alphabet
 » By Journal
 » By Subjects
 » Malaysian Journals
 » By Type
 » By Year
 » By Latest Additions
 
 
   » By Author
 » Top 20 Authors
 » Top 20 Article
 » Top Journal Cited
 » Top Article Cited
 » Journal Citation Statistics
 » Usage Since Sept 2007


 
 
 

Login | Create Account

Bcl-2 Expression and Clinico-Pathological Correlations in Invasive Ductal Carcinoma of the Breast

Al-Joudi, Fawwaz Shakir, and Iskandar Zulkarnain A., (2010) Bcl-2 Expression and Clinico-Pathological Correlations in Invasive Ductal Carcinoma of the Breast. Jurnal Sains Kesihatan Malaysia, 8 (2). pp. 59-64. ISSN 1675-8161

[img]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
129Kb

Official URL: http://www.fsk.ukm.my/journal/vol8(2).html

Affiliations

Universiti Kebangsaan Malaysia. Faculty of Allied Health Sciences
Universiti Sains Malaysia. School of Medical Sciences

Abstract

Bcl-2 is an anti-apoptotic protein belonging to a family of proteins that act as regulators of apoptosis in mammalian
cells. Bcl-2 expression has previously been reported in normal breast ductal cells and its involvement in the hormonal regulation of hyperplasia and involution was further suggested, and it was thought to be expressed through hormonedependent pathways. Bcl-2 is a cytoplasmic oncoprotein which is highly expressed in human solid tumours. In breast cancer cells, however, Bcl-2 expression is down regulated, the exact mechanism and the effects of which are not clearly defined, as bcl-2 expression appears to be inversely correlated with the presence of p53 mutations. This work aimed at investigating the expression of bcl-2 in invasive ductal carcinoma of the breast utilizing an immunohistochemistry assay as well as studying the clinical correlations of bcl-2. Bcl-2 was detected in 43.7% of 382 invasive ductal carcinoma study cases. Its expression correlated positively, with lower age of patients, higher histological grades, large tumour sizes, estrogen receptor positivity and progesterone receptor negativity. However, the statistical correlations
were weak. With the data obtained, it was found that the expression of bcl-2 correlated with unfavourable prognoses.
Furthermore, bcl-2 detection alone may not be very helpful in consolidating a clinical diagnosis.

Item Type:Journal
Additional Information:Thanks are due to the technical staff at the Department of Pathology, Hospital USM for their technical assistance. This work was supported by a USM short-term grant.
Keywords:Invasive ductal carcinoma; bcl-2; clinico-pathological correlations
Subjects:R Medicine, Dentistry, Pharmacy, Nursing
ID Code:11877

Al-Joudi, F.S., Iskandar, Z.A., Hasnan, J., Rusli, J., Yatiban, K., Imran, A.K., Marzouki, A. & Zakaria, J. 2007. Expression of survivin and its clinicopathological correlations in invasive ductal carcinoma of the breast: A study in the North-East of Malaysia. Singapore Med. J. 48(7): 607-614.

Al-Moundhri, M., Nirmala, V., Al-Mawaly, K., Ganguly, S.,

Burney, I., Rizvi, A. & Grant, C. 2003. Significance of p. 53, Bcl-2, and HER-2/neu protein expression in Omani Arab

female with breast cancer. Pathol. Oncol. Res. 9(4): 226-31.

Arun, B., Kilic, G., Yen, C., Foster, B., Yardley, D., Gaynor, R. & Ashfaq, R. 2003. Correlation of Bcl-2 and p.53 expression in primary breast tumors and corresponding metastatic lymph nodes. Cancer 98(12): 2554-2559.

Barbareschi, M., Caffo, O., Veronese, S., Leek, RD., Fina, P., Fox, S., Bonzanini, M., Girlando, S., Morelli, L., Eccher, C., Pezzela, F., Doglioni, C., Dalla Palma, P. & Harris, A. 1996. Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum. Pathol. 27: 1149-1155.

Dimitrakakis, C., Konstadoulakis, M., Messaris, E., Kymionis, G., Karayannis, M., Panoussopoulas, D., Michalas, S. & Androulakis, G. 2002. Molecular markers in breast cancer: Can we use c-erbB-2, p53, bcl-2 and bax gene expression as prognostic factors. The Breast 11: 279-285.

Eissa, S., Labib, R., Khalifa, A., Swelam, N., Khalil, F. & El- Shenawy, A.M. 1999. Regulators of apoptosis in human

breast cancer. Clin. Biochem. 32: 321-326.

El-Ahmady, O., el-Salahy, E., Mahmoud, M., Wahab, M.A., Eissa, S. & Khalifa, A. 2002. Multivariate analysis of bcl-2,apoptosis, p53 and HER-2/neu in breast cancer: a shortterm

follow-up. Anticancer Res. 22(4): 2493-2499.

Formby, B. & Wiley, T.S. 1999. Bcl-2, survivin and variant CD44 v7-v10 are downregulated and p53 is upregulated in breast cancer cells by progesterone: inhibition of cell growth and induction of apoptosis. Mol. Cell. Biochem. 202(1-2): 53-61.

Giatromanolaki, A., Sivridis, E., Koukourakis, M., Elleftherekis, A., Anastasiadis, P. & Agnantis, N. 2001. Inverse association of bcl-2 and microvessel density in breast cancer. Arch. Oncol. 9: 21.

Gursan, N., Karakok, M., Sari, I. & Gursan, M.S. 2001. The

relationship between expression of p.53/Bcl-2 and

histopathological criteria in breast invasive ductal carcinomas. Int. J. Clin. Pract. 55(9): 589-590.

Hamilton, A., Larsimont, D., Paridaens, R., Drijkoningen, M., van de Vijver, M., Bruning, P., Hanby, A., Houston, S.,

Treilleux, I., Guastalla, J.P., Van Vreckem, A., Slyvester, R. & Piccarct, M. 2000. A study of the value of p.53, HER2,

and Bcl-2 in the prediction of response to doxorubicin and

paclitaxel as single agents in metastatic breast cancer: a

companion study to EORTC 10923. Clin. Breast Cancer

1(3): 233-240.

Heiser, D., Labi, V., Erlacher, M. & Villunger, A. 2004. The Bcl-2 protein family and its role in the development of neoplastic disease. Experimental Gerontol. 9: 1125-1135.

Ioachim, E.E., Malamou-Mitsi, V., Kamina, S.A., Goussia, A.C. & Agnantis, N.J. 2000. Immunohistochemical expression of bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices. Anticancer Res. 20 (6B): 4221-4225.

Jansen, R.L., Joosten-Achjanie, S.R., Volovies, A., Arends, J.W., Hupperets, P.S., Hillen, H.F. & Schounten, H.C. 1998.

Relevance of the expression of bcl-2 in combination with

p53 as a prognostic factor in breast cancer. Anticancer Res.

18(16A): 4455-4462.

Le, M.G., Maathieu, M.C., Douc-Rasy, S., Bihan, M.L.L., All,

H.A.E., Spielman, M. & Riou, G. 1999. C-myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: evidence of a link between bcl-2 protein overexpression and a lower risk of metastasis and death in operable patients. Int. J. Cancer 84: 562-567.

Linjawi, A., Kontogiannea, M., Halwani, F., Edwardes, M. &

Meterissian, S. 2004. Prognostic significance of p53, bcl-2,

and Bax expression in early breast cancer. J. Am. Coll. Surg. 198: 83-90.

Malamou-mitsi, V., Gogas, H., Dafni, U., Bourli, A., Fillipidis, T., Sotiropoulou, M., Vlachodimitropoulos, D.,

Papadopoulos, S., Tzaida, O., Kafiri, G., Kyriakou, V.,

Markaki, S., Papaspyrou, I., Karagianni, E., Pavlakis, K.,

Toliou, T., Scopa, C., Papakostas, P., Bafaloukos, D.,

Christodoulou, C. & Fountzilas, G. 2006. Evaluation of the

predictive and prognostic value of p53 and bcl-2 in breast

cancer patients participating in a randomized study with

dose-dense sequential adjuvant chemotherapy. Ann. Oncol.

17(10): 1504-11.

Martinez-Arribas, F., Alvarez, T., Del Val, G., Martin-Garabato, E., Nunez-Villar, M.J., Lucas, R., Sanchez, J., Tejerina, A. & Schneider, J. 2007. Bcl-2 expression in breast cancer: a comparative study at the mRNA and protein level. Anti-Cancer Res. 27(1A): 219-22.

Mbonde, M.P., Amir, H., Akslen, L.A. & Kitinya, J.N. 2001.

Expression of oestrogen and progesterone receptors Ki-67,

p53 and Bcl-2 proteins, cathepsin D, urokinase plasminogen

activator and urokinase plasminogen activator-receptors in

carcinoma of the female breast in African population. East

African Med. J. 78(7): 360-365.

Moran, M.S., Yang, Q. & Haffty, B.G. 2009. The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology. Breast J. 15(6): 571-8.

Moulder, S.L., Symmans, W.F., Booser, D.J., Madden, T.L.,

Lipsanen, C., Yuan, L., Brewster, A.M., Cristofanilli, M.,

Hunt, K.K., Buchholz, T.A., Zwiebel, J., Valero, V.,

Hortobagyi, G.N. & Esteva, F.J. 2008. Phase I/II study of

G3139 (Bcl-2 antisense oligonucleotide) in combination with

doxorubicin and docetaxel in breast cancer. Clin. Cancer Res. 14(23): 7909-16.

Mullauer, L., Gruber, P., Sebinger, D., Buch, J., Wohlfart, S. & Chott, A. 2001. Mutations in apoptosis genes: a pathogenetic factor for human disease. Mutation Res. 488: 211- 231.

Murrillo-Oritz, B., Astudillo-De la Vega, H., Castillo-Medina, S., Malacara, J.M. & Benitez-Bribiesca, L. 2006. Telomerase activity, estrogen receptors (alpha, beta), bcl-2 expression in human breast cancer and treatment response. BMC Cancer 6: 206.

Park, S.H., Kim, H. & Song, B.J. 2002. Down regulation of bcl-2 expression in invasive ductal carcinomas is both estrogen and progesterone receptor dependent and associated with poor prognostic factors. Pathol. Oncol. Res. 8(1): 26-30.

Pusztai, L., Krishnamurti, S., Cardona, P., Sneige, N., Esteva, F.J., Volchenok, M., Breitenfelder, P., Kau, S.W., Takayama, S., Krajewski, S., Reed, J.C. & Bast, R.C. 2004. Expression of BAG-1 and Bcl-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer. Cancer Invest. 22(2): 248-256.

Robertson, J.D., Orrenius, S. & Zhivotovsky, B. 2000. Review: Nuclear events in apoptosis. J. J. Struct. Biol. 129: 346-358.

Sato, T., Yuyama, Y., Watabe, K., Okazaki, A., Toda, K., Okazaki, M. & Hirata, K. 1997. Detection of p53 gene mutations in fine-needle aspiration biopsied breast cancer specimens: correlation with nuclear p53 accumulations and tumor DNA aneuploidy patterns. Cancer Let. 115: 47-55.

Schinzel, A., Kaufmann, T. & Borner, C. 2004. Bcl-2 family

members: intracellular targeting, membrane-insertion, and

changes in subcellular localization. Biochimica et Biophysica Acta 1644: 95-105.

Sierra, A., Castellsague, X., Tortola, S., Escobedo, A., Lloveras, B., Peinado, M.A., Moreno, A. & Fabra, A. 1996. Apoptosis loss and bcl-2 expression: key determinants of lymph nodes metastases in T1 breast cancer. Clin. Cancer Res. 2(11): 1887-1894.

Sirvent, J.J., Aguilar, M.C., Olona, M., Pelegri, A., Blazquez, S. & Gutierrez, C. 2004. Prognostic value of apoptosis in breast cancer (pT1 – pT2). A TUNEL, p53, bcl-2, bag-1 and Bax immunohisrochemical study. Histol. Histopathol. 19(3): 759-770.

Strasser, A., Huaang, D.C.S. & Vaux, D.L. 1997. The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. Biochimica et Biophysica Acta. 1333: 1151-178.

Subhawong, A.P., Nassar, H., Halushka, M.K., Illei, P.B., Vang, R. & Argani, P. 2010. Heterogeneity of Bcl-2 expression in metastatic breast carcinoma. Mod. Pathol. (Epub ahead of print).

Sun, J.X., Meng, Z.X., Ly, J.H. & Sun, Y.J. 2006. Troglitazone sensitizes effect of epirubicin on breast cancer cells. Ai Zheng 25(8): 960-966.

Suzuki, K., Kazui, T., Yoshida, M., Uno, T., Kobasyashi, T.,

Kimura, T., Yoshida, T. & Sugimura, H. 2004. Drug-induced

apoptosis and p53, bcl-2 and bax expression in breast cancer

tissues in vivo and in fibroblast cell in vitro. Jap. J. Clin. Onco. 29(7): 323-331.

Takei, H., Oyama, T., Lino, Y., Horiguchi, J., Hikino, T., Maeruma, M., Nagaoka, H., Iijima, K., Yokoe, T., Nakajima, T. & Morishita, Y. 1995. Clinical significance of

immunohistochemical bcl-2 expression in invasive breast

carcinoma. Oncol. Rep. 6(3): 575-581.

Townsend, P.A., Dublin, E., Hart, I.R., Kao, R.H., Hanby, A.M., Cutress, R.I., Poulsom, R., Ryder, K., Barnes, D.M. &

Packham, G. 2002. BAG-i expression in human breast cancer:

interrelationship between BAG-1 RNA, protein, HSC70

expression and clinico-pathological data. J. Pathol. 197(1):

51-9.

Troncone, G., Zeppa, P., Vetrani, A., D’Arcangelo, A., Fulciniti, F., De Divitiis, B. & Palombini, L. 1995. Bcl-2 protein in breast cancer cells obtained by fine needle aspiration (FNA): a preliminary report. Cytopathol. 6(4): 219-25.

Van-Slooten, H.J., van de Vijver, M.J., van de Velde, C.J. & van Dierendonck, J.H. 1998. Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. Br. J. Cancer 77(5): 789-796.

Villar, E., Redondo, M., Rodrigo, I., Garcia, J., Avilla, E. & Matilla, A. 2001. Bcl-2 expression and apoptosis in primary and metastatic breast carcinomas. Tumour Biol. 22(3): 137-145.

Won, K.Y., Kim, G.Y., Kim, Y.W., Song, J.Y. & Lim, S.J. 2010. Clinicopathologic correlation of beclin-1 and bcl-2 expression in human breast cancer. Hum. Pathol. 41(1): 107-12.

Yang, Q., Sakurai, T., Jing, X., Utsunomiya, H., Shan, L.,

Nakamura, Y., Nakamura, M., Oura, S., Suzuma, T., Yoshimura, G., Umemura, T., Kokawa, Y. & Kakudom K.

1999. Expression of Bcl-2, but not Bax, correlates with

estrogen receptor status and tumor proliferation in invasive

breast carcinoma. Pathol. Int. 49: 775-780.

Yang, Q., Sakurai, T., Yoshimura, G., Umemura, T., Nakamura,

M., Nakamura, Y., Mori, I. & Kakudo, K. 2003. Prognostic

value of bcl-2 in invasive breast cancer receiving

chemotherapy and endocrine therapy. Oncol. Rep. 10(1):

121-5.

Yang, Q., Mori, I. & Sakurai, T. 2001. Correlation between nuclear grade and biological prognostic variables in invasive breast cancer. Breast Cancer 8(2): 105-110.

Zhang, G.J., Kimijima, I., Abe, R., Watanabe, T., Kanno, M.,

Hara, K. & Tsuchiya, A. 1998. Apoptotic index correlates

to bcl-2 and p53 protein expression, histological grade and

prognosis in invasive breast cancers. Anticancer Res 18(3B):

1989-98.

Repository Staff Only: item control page
 
 
 
 
 
 
© Copyright 2007 MyAIS Faculty of Computer Science and Information Technology, University of Malaya – All Rights Reserved. Malaysian Abstracting and Indexing System is powered by EPrints 3 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.